OKYO Pharma Limited (OKYO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

OKYO Pharma Limited (OKYO) Healthcare & Pipeline Overview

OKYO Pharma Limited is a preclinical biopharmaceutical company dedicated to developing novel therapeutics for inflammatory eye diseases and ocular pain, with a focus on innovative solutions such as OK-101 and OK-201 aimed at addressing significant unmet medical needs.

What Is the Investment Thesis for OKYO?

OKYO Pharma Limited presents a unique investment thesis centered around its innovative pipeline targeting inflammatory eye diseases and ocular pain. The company's lead candidate, OK-101, is positioned within a growing market for dry eye treatments, projected to reach $5.4 billion by 2026, driven by increasing prevalence and awareness of the condition. Additionally, OK-201, targeting neuropathic ocular pain, taps into an underserved market with significant potential. The company’s focus on niche therapeutic areas provides a competitive advantage, as it seeks to fulfill unmet medical needs. While the biotechnology sector is inherently risky, with high rates of failure in drug development, OKYO's specialized focus and commitment to rigorous scientific research may enhance its chances of successful product development. The lack of a dividend and a small market capitalization of $55.1M reflect the early-stage nature of the company, which is typical for preclinical biopharmaceutical firms. Investors may want to evaluate the potential for substantial returns if OKYO successfully advances its candidates through clinical trials and regulatory approvals.

Based on FMP financials and quantitative analysis

OKYO Key Highlights

Market Cap of $55.1M reflects the early-stage nature of the company and its preclinical focus.

• Lead product OK-101 targets a growing market for dry eye disease, projected to reach $5.4 billion by 2026.
• OKYO Pharma operates with a lean team of three employees, allowing for agile decision-making.
• The company is developing OK-201 for neuropathic ocular pain, addressing an underserved market.
• Beta of -0.12 indicates lower volatility compared to the market, suggesting relative stability.

Who Are OKYO's Competitors?

OKYO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OKYO's Key Strengths?

Innovative product pipeline targeting specific ocular conditions.

• Experienced leadership with a focus on research and development.
• Agile operational model with a small team for efficient decision-making.

What Are OKYO's Weaknesses?

Limited financial resources typical of early-stage biopharmaceutical companies.

• Dependence on successful clinical trial outcomes for product advancement.
• Small employee base may limit operational capacity.

What Could Drive OKYO Stock Higher?

OKYO catalyst: Progression of OK-101 through clinical trials, with potential milestones expected in the next 12-18 months.

• Development of OK-201 for neuropathic ocular pain, with ongoing research and preclinical studies.
• Potential partnerships or collaborations with larger pharmaceutical companies to enhance product development.

What Are the Key Risks for OKYO?

Financial-distress signal — its Altman Z-Score of -8.09 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• High risk of failure in drug development, particularly in preclinical and clinical trial phases.
• Regulatory challenges that could delay product approvals and market entry.
• Competition from established pharmaceutical companies with more resources and market presence.

What Are the Growth Opportunities for OKYO?

• Growth opportunity 1: The global dry eye disease market is projected to reach $5.4 billion by 2026, driven by increasing awareness and prevalence. OKYO's lead product, OK-101, is well-positioned to capture a share of this growing market, particularly as it advances through clinical trials and approaches potential regulatory approval.
• Growth opportunity 2: The neuropathic ocular pain market is currently underserved, with limited effective treatment options available. OK-201 aims to fill this gap, potentially tapping into a market that is expected to grow as awareness of neuropathic pain conditions increases, alongside advancements in treatment methodologies.
• Growth opportunity 3: As the biotechnology sector continues to attract investment, OKYO Pharma could benefit from partnerships or collaborations with larger pharmaceutical companies seeking innovative therapies. Such alliances could provide additional resources for clinical trials and accelerate the development timeline for its products.
• Growth opportunity 4: The increasing prevalence of chronic eye diseases due to an aging population presents a long-term growth opportunity for OKYO. As demographic trends shift, the demand for effective treatments for conditions like dry eye and ocular pain is expected to rise, positioning OKYO favorably within the market.
• Growth opportunity 5: Advances in biotechnology and personalized medicine may open new avenues for OKYO's research and development efforts. By leveraging cutting-edge technologies, the company could enhance its product offerings and improve patient outcomes in the ocular therapeutics space.

What Threats Does OKYO Face?

• High competition in the biotechnology sector.
• Regulatory hurdles and lengthy approval processes.
• Market volatility affecting funding and investment opportunities.

What Are OKYO's Competitive Advantages?

• Focused expertise in niche therapeutic areas within ophthalmology.
• Innovative product pipeline targeting unmet medical needs.
• Agile operational structure allowing for quick adaptation to market changes.
• Potential for strategic partnerships with larger firms in the biopharmaceutical industry.
• Strong emphasis on research and development to drive product innovation.

What Does OKYO Do?

Founded in 2007 and headquartered in London, OKYO Pharma Limited is a preclinical biopharmaceutical company focused on developing innovative therapeutics for patients suffering from inflammatory eye diseases and ocular pain. The company has established itself within the biotechnology sector, concentrating its efforts on creating treatments that address significant unmet medical needs in ophthalmology. OKYO's lead product, OK-101, is designed for the treatment of dry eye disease, a condition that affects millions of individuals worldwide and is characterized by discomfort and visual disturbances. In addition to OK-101, the company is advancing its pipeline with OK-201, a lipidated-peptide preclinical analogue candidate derived from bovine adrenal medulla, aimed at treating neuropathic ocular pain. This product reflects OKYO's commitment to leveraging cutting-edge science to develop effective therapies for complex ocular conditions. With a small team of three employees, OKYO operates with a lean structure, allowing for agile decision-making and focused development efforts. The company’s strategic initiatives are aimed at navigating the challenging landscape of biopharmaceutical development, where regulatory hurdles and clinical trial complexities are prevalent. As it progresses through the preclinical stages, OKYO Pharma is positioned to make significant contributions to the field of ophthalmology, addressing both chronic and acute ocular conditions that impact patient quality of life.

What Products and Services Does OKYO Offer?

• Develop therapeutics for inflammatory eye diseases and ocular pain.
• Focus on preclinical research and development of innovative biopharmaceuticals.
• Lead product OK-101 targets dry eye disease.
• Develop OK-201 for neuropathic ocular pain.
• Incorporated in 2007 and headquartered in London, UK.
• Operate with a small, agile team to facilitate rapid decision-making.

How Does OKYO Make Money?

• Generate revenue through the development and commercialization of biopharmaceutical products.
• Focus on securing partnerships and collaborations with larger pharmaceutical companies.
• Aim to advance products through clinical trials to achieve regulatory approval.
• Potential for licensing agreements once products are commercialized.
• Engage in research and development to innovate within the ophthalmic therapeutics market.

What Industry Does OKYO Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in therapeutic areas with unmet medical needs. Within this context, OKYO Pharma Limited is positioned to capitalize on the increasing demand for effective treatments for eye diseases, particularly as the prevalence of conditions like dry eye disease rises. The competitive landscape includes various established pharmaceutical companies, but OKYO’s focus on niche therapeutic areas may provide a unique advantage in addressing specific patient needs.

Who Are OKYO's Key Customers?

• Patients suffering from inflammatory eye diseases and ocular pain.
• Healthcare providers and ophthalmologists seeking effective treatment options.
• Pharmaceutical partners interested in collaboration for product development.
• Investors looking for opportunities in the biotechnology sector.
• Regulatory bodies for drug approval and compliance.

Over the past six months, OKYO Pharma Limited insiders filed 19 SEC Form 4 transactions — 0 sales and 19 purchases. On net that is roughly 545K shares acquired (about $893K) — insiders putting money in tends to read as conviction.

OKYO Pharma Limited has beaten Wall Street's EPS estimate in 2 of its last 3 reported quarters — more hits than misses. Reported results have landed about 5.9% above estimates on average.

OKYO Pharma Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.09 places it in the distress zone, a signal of elevated financial risk.

Return on equity for OKYO Pharma Limited stands at 102.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -99.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.58 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -8.1%, the inverse of the P/E and a quick read on earnings relative to price.

OKYO Pharma Limited (OKYO) Valuation Context

Valued at $55.1M, OKYO is classified as a micro-cap stock. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $1.44, that implies approximately 248% upside potential. Relative to its peer group, OKYO's quantitative score of 31/100 is below the peer average of 80/100.

OKYO Revenue & Earnings Trend

In Q4 FY2026, OKYO generated $0 in top-line revenue. The company recorded a net loss of $6.4M, with diluted EPS of $-0.17. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, OKYO averaged $-0.09 in diluted EPS.

Company Profile

OKYO Pharma Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Robert J. Dempsey. OKYO has traded publicly since 2022.

OKYO Financials

OKYO Latest News

OKYO Analyst Consensus

OKYO MoonshotScore

OKYO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources